Glycolithocholic acid

• CAT Number: R012628
• CAS Number: 474-74-8
• Molecular Formula: C26H43NO4
• Molecular Weight: 433.62
• Purity: ≥95%
• Synonyms: 2-[[(4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
• InChI: InChI=1S/C26H43NO4/c1-16(4-9-23(29)27-15-24(30)31)20-7-8-21-19-6-5-17-14-18(28)10-12-25(17,2)22(19)11-13-26(20,21)3/h16-22,28H,4-15H2,1-3H3,(H,27,29)(H,30,31)/t16-,17-,18-,19+,20-,21+,22+,25+,26-/m1/s1
• InChIKey: XBSQTYHEGZTYJE-OETIFKLTSA-N
• SMILES: CC(CCC(=O)NCC(=O)O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C

Glycolithocholic acid (Cat No.: R012628) is a conjugated bile acid, formed from lithocholic acid and glycine, that plays a role in bile acid metabolism and enterohepatic circulation. It contributes to lipid digestion, cholesterol homeostasis, and signaling through bile acid receptors such as FXR and TGR5. Abnormal levels of glycolithocholic acid are associated with cholestasis, liver injury, and gastrointestinal disorders. In research, it is widely used to study bile acid biochemistry, gut microbiota interactions, and metabolic disease mechanisms, supporting hepatology and gastrointestinal pharmacology.

Reference

[1]. Tanno N, et, al. Biliary lipid composition in heterozygous familial hypercholesterolemia and influence of treatment with probucol. Dig Dis Sci. 1994 Jul;39(7):1586-91.
[Content Brief]

[2]. Ang ZH, et, al. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J Gastroenterol. 2021 Jun 28;27(24):3609-3629.
[Content Brief]

[3]. Bansal S, et, al. Inhibition of Human Sulfotransferase 2A1-Catalyzed Sulfonation of Lithocholic Acid, Glycolithocholic Acid, and Taurolithocholic Acid by Selective Estrogen Receptor Modulators and Various Analogs and Metabolites. J Pharmacol Exp Ther. 2019 Jun;369(3):389-405.
[Content Brief]

[4]. Sanyal AJ, et, al. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. JHEP Rep. 2021 Feb 19;3(3):100255.
[Content Brief]